Cullinan Oncology LLC (CGEM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $667.39M
Last updated: Nov 17, 2026 at 4:20 PM ET
Cullinan Oncology LLC (CGEM) Statistics
Cullinan Oncology LLC (CGEM) has a market cap of $667.39M and an enterprise value of $579.13M. Its share count is up 8.17% from a year earlier. It holds $88.26M more cash than debt, 13.22% of its market cap.
Total Valuation
Enterprise value is 13.22% below the market cap, as cash exceeds debt.
| Market Cap | $667.39M |
|---|---|
| Enterprise Value | $579.13M |
| Latest price (Nov 17, 2026) | $9.28 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 8.48% over 52 weeks and trades 39.62% below its 50-day average.
| Beta (1Y) | 1.64 |
|---|---|
| 52-Week Change | +8.48% |
| 1-Month Change | -33.66% |
| 3-Month Change | -58.81% |
| 6-Month Change | -34.57% |
| 5-Year Change | -32.36% |
| Total Return (1Y) | +8.48% |
| Total Return (3Y CAGR) | +1.77% |
| Total Return (5Y CAGR) | -13.61% |
| Return vs SPY (1Y) | -2.95% |
| Max Drawdown (1Y) | -59.59% |
| Max Drawdown (3Y) | -80.41% |
| Sharpe Ratio (1Y) | 0.10 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $15.37 |
| 200-Day Average | $15.79 |
| 52-Week Range | $8.23 to $23.19 |
| RSI (14 Days) | 27.3 |
| Average Volume (20 Days) | 902.19K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.43x current liabilities.
| Current Ratio | 7.43x |
|---|---|
| Quick Ratio | 7.43x |
Returns and Efficiency
| Return on Assets (ROA) | -63.08% |
|---|---|
| ROA (5Y Average) | -20.80% |
Scores
CGEM has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$79.00K |
| Operating Income | -$218.81M |
| Pretax Income | -$203.47M |
| Net Income | -$203.47M |
| Reported EPS (TTM) | -$3.07 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $88.26M |
|---|---|
| Total Debt | $0 |
| Net Cash | $88.26M |
| Net Cash Per Share | $1.37 |
| Working Capital | $258.02M |
| Shareholder Equity | $0 |
| Book Value Per Share | $4.35 |
| Total Assets | $322.56M |
| Total Liabilities | $41.27M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$165.46M |
|---|---|
| FCF Per Share | -$2.69 |
| Depreciation and Amortization | $2.00M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -19.30% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -19.30% |
Dividends and Yields
CGEM does not pay a dividend.
| Buyback Yield | -0.54% |
|---|---|
| Shareholder Yield | -0.54% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CGEM
What is CGEM's market cap?
Cullinan Oncology LLC has a market cap of $667.39M. Its enterprise value, which adds debt and subtracts cash, is $579.13M.
How many shares of CGEM are outstanding?
Cullinan Oncology LLC has 64.60M shares outstanding. The count is up 8.17% from a year earlier.
Does CGEM pay a dividend?
No. Cullinan Oncology LLC does not pay a dividend.
How much debt does CGEM have?
Cullinan Oncology LLC has $0 of total debt and $88.26M of cash and equivalents, a net cash position of $88.26M.
CGEM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors